Meibomian Gland Dysfunction Clinical Trial
Official title:
Effect of Meibomian Gland Probing on Ocular Surface in Ocular Rosacea
Meibomian glands (MG) are modified sebaceous glands associated with the tarsus (collagenous structural component) of the upper and lower eyelids. Meibomian glands produce lipid-based secretions which are an integral and stabilizing part of the tear film. In blepharitis and ocular rosacea (two known causes of obstructive meibomian gland dysfunction (o-MGD), inflammation of the lid margins causes blockage of the meibomian gland orifices, changes in glandular secretions, and dropout of the glands themselves. This limits the production, secretion, and quality of meibum. With less oil in the tear film, the aqueous portion of tears is not stable and evaporates quickly which leads to dry eye.
Meibomian gland probing is a relatively new, safe, and effective technique for treating
obstructive meibomian gland dysfunction (o-MGD). It involves topical anesthesia of the eyelid
margins and insertion of a 2 mm or 4 mm sterile, beveled, solid stainless steel probe at the
slit lamp. Meibomian gland probing has been reported to alleviate symptoms (lid tenderness /
lid margin congestion) of o-MGD (Maskin, 2010). It has also been shown to improve meibum
lipid levels, viscosity, and tear breakup time (Nakayama, Kawashima, Kaido, Arita, & Tsubota,
2015). Though probing has been investigated in a few small studies of o-MGD, only one small
study of 10 participants has investigated meibomian gland probing in ocular rosacea (Wladis,
2012). This study showed improvement in ocular surface disease index (OSDI, a standardized
questionnaire assessing dry eye) but did not show objective improvement by way of examination
findings or analysis of meibum (Wladis, 2012).
In our study, Investigators intend to further investigate meibomian gland probing in
participants with diagnosed ocular rosacea. Investigators hypothesize that after probing of
one eye, Investigators will note improvements in participants symptoms as reflected in
improvement in OSDI scores, Reductions in Inflamma-Dry measures (measure of matrix
metalloproteinase (MMP-9), an inflammatory marker elevated in tears of participants with dry
eye), decreased tear fluid osmolarity, decreased meibum viscosity on expression . Objective
improvement in lid margin disease (noting collarettes, pitting, telangiectasia of lid
margins, thickening / irregularity of lid margins, lid margin tenderness; improvement in tear
break up time (TBUT); and improvement in corneal fluorescein / lissamine green staining).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05062564 -
Efficacy of LipiFlow in Patients Affected by Meibomian Gland Dysfunction in Reducing Post-cataract Surgery Dry Eye
|
N/A | |
Completed |
NCT04884243 -
Safety, Efficacy and Pharmacokinetics of CBT-006 in Patients With Meibomian Gland Dysfunction
|
Phase 2 | |
Active, not recruiting |
NCT04425551 -
Effect of Micropulse Laser on Dry Eye Disease Due to Meibomian Gland Dysfunction
|
N/A | |
Terminated |
NCT02596919 -
Fast Infrared Meibography (Photography)
|
N/A | |
Completed |
NCT01207752 -
The Efficacy of an Ocular Emulsion in Meibomian Gland Dysfunction
|
N/A | |
Completed |
NCT05162261 -
to Evaluate the Effectiveness and Safety of the Tixel® , VS LipiFlow® in the Treatment of Meibomian Gland Dysfunction
|
N/A | |
Recruiting |
NCT06064071 -
Clinical Study Evaluating Nordlys™ SWT IPL for Dry Eye Disease (DED) Due to MGD
|
N/A | |
Completed |
NCT03652051 -
A Multicenter Study Evaluating AZR-MD-001 in Patients With Meibomian Gland Dysfunction and Evaporative Dry Eye Disease (DED)
|
Phase 2 | |
Recruiting |
NCT03767530 -
Efficacy and Safety of Thermic Devices in the Treatment of Meibomian Gland Dysfunction
|
N/A | |
Active, not recruiting |
NCT05577910 -
Vectored Thermal Pulsation, Intense Pulsed Light, and Eyelid Warm Compress Therapies for MGD
|
N/A | |
Completed |
NCT04889950 -
Clinical Study to Evaluate the Safety and Effectiveness of The Tixel Fractional System in the Treatment of Meibomian Gland Disfunction
|
N/A | |
Recruiting |
NCT06004895 -
Mechanisms of Light-based Therapies for Dry Eye Disease
|
N/A | |
Completed |
NCT04147962 -
Intense Pulsed Light in Meibomian Gland Dysfunctions
|
||
Completed |
NCT02256969 -
Intraductal Meibomian Gland Probing Trial
|
Phase 4 | |
Recruiting |
NCT05089591 -
Intense Pulsed Light in Meibomian Gland Dysfunction
|
N/A | |
Completed |
NCT04500821 -
Evaluation of the LipiFlow System With a New Activator
|
N/A | |
Completed |
NCT03318874 -
Optimization of the Treatment of Dry Eye Disease Caused by Meibomian Gland Dysfunction
|
Phase 4 | |
Completed |
NCT06278584 -
iLux Treatment for Meibomian Gland Dysfunction
|
N/A | |
Recruiting |
NCT04052841 -
Morphological Analysis of Meibomian Glands
|
N/A | |
Completed |
NCT05028491 -
The Influence of Meibomian Gland Expression on Corneal Aberrations in MGD Patients
|